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Synthesis and characterization of azole isoﬂavone
inhibitors of aromatase
John C Hackett, Young-Woo Kim, Bin Su and Robert W. Brueggemeier
Introduction
Estrogens are important in the growth of breast cancers
in both pre- and post-menopausal women and, estrogen
sensitivity in breast cancer increases with patient age.
Two-thirds of breast cancer tumors in post-menopausal
women are positive for estrogen and/or progesterone
receptors, compared to pre-menopausal women where
the presence of these receptors appears in less than half
of tumors. The endogenous ligands for these receptors,
estrogens and progestins, stimulate cell proliferation di-
rectly by increasing the rate of early response genes and
indirectly through the stimulation of growth factors.1
Such dependence on sex steroids for tumor growth
makes hormonal therapy an inviting strategy for
treatment.2
Two general strategies have developed for the treatment
of hormone-dependent breast cancer. The ﬁrst strategy
is to block estrogen receptor action by disrupting its
interaction with and activation by estradiol. Antiestro-
gens, such as tamoxifen, bind to the estrogen receptor
and interfere with the transcription of estrogen-induced
genes. The eﬃcacy of tamoxifen has been established in
the treatment of post-menopausal, hormone-responsive
breast cancer.3 Tamoxifen increases long-term survival,
reduces recurrences, and has few side eﬀects. In addition
to tamoxifens antagonistic eﬀects in breast tissue, it also
behaves as a weak or partial agonist in other tissues.
While exhibiting antagonistic activity in the breast, the
partial agonist eﬀects in other parts of the body have
lead to the formation of secondary tumors of the liver
and uterus.4 A second pharmacological approach is to
block estradiol synthesis catalyzed by the cytochrome
P450 enzyme aromatase (CYP19). Aromatase has been
a particularly attractive target for inhibition in the treat-
ment of hormone-dependent breast cancer since the aro-
matization of androgen substrates is the terminal and
rate-limiting step in estrogen biosynthesis.5–8
In addition to the large number of aromatase inhibitors
that have arisen from medicinal chemistry eﬀorts in
pharmaceutical and academic laboratories,5–9 a signiﬁ-
cant number of natural product aromatase inhibitors
have been identiﬁed.10–12 The ﬂavonoids are one of the
largest classes of naturally occurring aromatase inhibi-
tors.10 Generally, ﬂavones and ﬂavanones have higher
aromatase inhibitory activity than isoﬂavones. Chrysin
and Biochanin A (BCA) are two of the most potent
examples of ﬂavone and isoﬂavone identiﬁed to date,
respectively (Fig. 1). The ﬂavone, chrysin, is 20-fold
more potent than BCA in terms of IC50 values.
11,12 This
large diﬀerence in potency is the likely reason why there
has been little eﬀort to develop aromatase inhibitors on
an isoﬂavone scaﬀold.
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heme iron. Taken together with the density functional
theory (DFT) calculations, these observations explain
the superior potency of the imidazole analog relies on
the availability of the nitrogen lone pair electrons to
coordinate with the aromatase P450 heme.
In general, imidazole isoﬂavone inhibitors presented in
this work share similar structure activity relationships
to those reported for 2-(4-pyridylmethyl)thioisoﬂav-
ones.14 Regardless of the 7-substituent, a decrease in po-
tency was observed when a methoxy group was
introduced at the 4 0-position. Additionally, the relative
decrease in potency is dependent on the nature of the
7-substituent. 4 0,7-Dimethoxy analog, 2b, is 2.6-fold less
potent than the 7-methoxy analog 2a. The loss of
potency is more pronounced when considering the 7-
benzyloxy analogs. The presence of the 4 0-methoxy in
2d results in a nine-fold loss of activity when compared
to 2c. 4 0,7-Dimethoxy-(4-pyridylmethylthio)isoﬂavone
and 7-benzyloxy-40-methoxy-2-(4-pyridyl-methylthio)iso-
ﬂavone are 1.2- and 2.5-times less active than their 4 0-H
analogs. This observation may indicate the nature of the
4 0-substituent may be a more important factor in the
imidazole isoﬂavones in terms of aromatase inhibition.
In enzyme kinetic studies, imidazole isoﬂavones 2a d
demonstrated typical competitive-type inhibition in the
Lineweaver Burk plots (Fig. 2 for 2c; plots for 2a, b, d
not shown) supporting their inhibition of aromatase
by competing with the natural substrate for the active
site. Ki/Km ratios of imidazole isoﬂavones were calcu-
lated as relative inhibitory potency and the same activity
trend is observed as in the dose response studies. Com-
pound 2c demonstrates 48-fold enhancement in potency
compared to the natural product lead, BCA. As reﬂected
by its relative potency, imidazole analog 2c is 4.4-fold
more potent than the widely characterized inhibitor
AG, which is in agreement within the expected experi-
mental uncertainty of the result determined in the
dose response studies (5.4-fold enhancement in potency
compared to AG). The results of the present enzyme ki-
netic studies emphasize the importance of these struc-
tural modiﬁcations for optimization of aromatase
inhibition by isoﬂavones.
Conclusion
Our recent work on 2-(4-pyridylmethylthio)isoﬂavones
demonstrated for the ﬁrst time that eﬀective isoﬂav-
one-based aromatase inhibitors can be constructed by
the introduction of appropriate nitrogen-containing het-
erocycle. This study further extends this concept that
aromatase inhibitory activity can be achieved with the
isoﬂavone nucleus by introduction of an appropriate
heme-coordinating nitrogen heterocycle at the 2-posi-
tion of the isoﬂavone. Comparable potency to the 2-
(4-pyridylmethylthio)isoﬂavones can be obtained by
introducing an imidazole moiety at the 2-position. En-
zyme kinetic analyses of imidazole isoﬂavones reveal
these compounds interact competitively with the aroma-
tase active site. As revealed by DFT calculations and the
diﬀerence spectra of ligand binding, the superiority of
this heterocycle to achieve aromatase inhibition may
lie in the electronic structure of the nitrogen heterocycle
itself. While investigations are currently underway to re-
solve further aspects of the enzyme ligand interactions,
these compounds are additional leads in our repertoire
of potent aromatase inhibitors.
Experimental section
Chemistry
Chemicals were commercially available and used as re-
ceived without further puriﬁcation, unless otherwise
noted. Moisture sensitive reactions were carried out un-
der a dry argon atmosphere in ﬂame-dried glassware.
Solvents were distilled before use under argon. Tetrahy-
drofuran was distilled from sodium metal in the pres-
ence of benzophenone; dichloromethane was distilled
from calcium hydride. Thin layer chromatography was
performed on pre-coated silica gel F254 plates (What-
man). Silica gel column chromatography was performed
using silica gel 60A (Merck, 230-400 Mesh). Melting
points were determined in open glass capillaries using
a Thomas Hoover apparatus and are uncorrected. Infra-
red spectra were recorded on a Nicolet Prote´ge´ 460
spectrometer using KBr pellets. High-resolution electro-
spray ionization mass spectra were obtained on the
Micromass QTOF Electrospray mass spectrometer at
The Ohio State Chemical Instrumentation Center. All
the NMR spectra were recorded on a Bruker DPX
250, or Bruker DRX 400 model spectrometer in either
DMSO-d6 or CDCl3. Chemical shifts (d) for
1H NMR
spectra are reported in parts per million to residual sol-
vent protons. Chemical shifts (d) for 13C NMR spectra
are reported in parts per million relative to residual sol-
vent carbons.
General method A for the preparation of 2-(alkyl-
sulfonyl)isoﬂavones (1a–d)
A mixture of 7-alkoxy-3-aryl-2-(methylthio)-4H-1-benzo-
pyran-4-one (8.0 mmol) and 3-chloroperoxybenzoic acid
(mCPBA) (4.14 g, 24 mmol) in CH2Cl2 (80 mL) were
stirred under reﬂux for 2 h. After the solvent was re-
moved under reduced pressure, the residue was
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Figure 4. Type II diﬀerence spectra of immunoaﬃnity puriﬁed human
placental aromatase induced by 50 lM compound 2a (blue) and
compound 3a (red).
4066
suspended in diethyl ether and hexane (1:1, 100 mL),
sonicated, and placed in a refrigerator overnight. The
insoluble solid was collected by ﬁltration, washed with
diethyl ether and hexane (1:1) several times, and recrys-
tallized from ethyl acetate to give desired product.
7-Methoxy-2-(methylsulfonyl)-3-phenyl-4H-1-benzo-
pyran-4-one (1a). Compound 1a was synthesized from 7-
methoxy-2-(methylthio)-3-phenyl-4H-1-benzopyran-4-
one (2.39 g, 8.0 mmol) using General Method A, and
2.59 g (98%) of the title compound was obtained as a
pale yellow solid: mp 208 210 C; HRMS calculated
for C17H14NaO5S (M+Na)
+ 353.0460, found 353.0459.
IR (KBr) 1648, 1622, 1604, 1569, 1436, 1326, 1256,
1203, 1155, 1134, 1100, 1052, 1029, 962, 825, 772, 755,
583 cm 1; 1H NMR (400 MHz, DMSO-d6) d 7.94 (d,
J = 8.9 Hz, 1H), 7.36 7.38 (m, 3H), 7.34 (d,
J = 2.3 Hz, 1H), 7.25 7.27 (m, 2H), 7.12 (dd, J = 8.9,
2.3 Hz, 1H), 3.91 (s, 3H), 3.30 (s, 3H); 13C NMR
(100 MHz, DMSO-d6) d 176.39, 165.70, 157.72, 157.47,
131.39, 129.98, 129.26, 128.41, 127.86, 124.68, 117.28,
117.03, 101.73, 57.30, 42.46.
7-Methoxy-3-(4-methoxyphenyl)-2-(methylsulfon-
yl)-4H-1-benzopyran-4-one (1b). Compound 1b was syn-
thesized from 7-methoxy-3-(4-methoxyphenyl)-2-(meth-
ylthio)-4H-1-benzopyran-4-one (2.63 g, 8.0 mmol)
using General Method A, and 2.68 g (93%) of the title
compound was obtained as a pale yellow solid: mp
227 228.5 C; HRMS calculated for C18H16NaO6S
(M+Na)+ 383.0565, found 383.0569. IR (KBr) 1646,
1618, 1610, 1570, 1509, 1438, 1337, 1311, 1261, 1246,
1203, 1176, 1141, 1100, 1024, 973, 955, 849, 773, 588,
539, 520, 482 cm 1; 1H NMR (400 MHz, DMSO-d6) d
7.94 (d, J = 8.9 Hz, 1H), 7.33 (d, J = 2.3 Hz, 1H), 7.19
(d, J = 8.6 Hz, 2H), 7.11 (dd, J = 8.9, 2.3 Hz, 1H), 6.94
(d, J = 8.7 Hz, 2H), 3.91 (s, 3H), 3.77 (s, 3H), 3.28 (s,
3H); 13C NMR (100 MHz, DMSO-d6) d 176.59, 165.65,
160.31, 157.75, 157.43, 132.81, 127.88, 124.37, 121.66,
117.24, 116.96, 113.96, 101.69, 57.27, 55.96, 42.44.
2-(Methylsulfonyl)-3-phenyl-7-(benzyloxy)-4H-1-
benzopyran-4-one (1c). Compound 1c was synthesized
from 2-(methylthio)-3-phenyl-7-(benzyloxy)-4H-1-benzo-
pyran-4-one (3.0 g, 8.0 mmol) using General Method A,
and 3.12 g (96%) of the title compound was obtained as
a white solid: mp 198 199 C; HRMS calculated for
C23H18NaO5S (M+Na)
+ 429.0773, found 429.0761. IR
(KBr) 1651, 1620, 1568, 1499, 1440, 1332, 1256, 1161,
1140, 1113, 1027, 1005, 975, 832, 775, 744, 700,
616 cm 1; 1H NMR (400 MHz, DMSO-d6) d 7.95 (d,
J = 8.9 Hz, 1H), 7.26 7.48 (m, 11H), 7.19 (dd, J = 8.9,
2.0 Hz, 1H), 5.28 (s, 2H), 3.29 (s, 3H); 13C NMR
(100 MHz, DMSO-d6) d 176.39, 164.66, 157.72, 157.37,
136.77, 131.94, 131.40, 129.99, 129.46, 129.27, 129.10,
128.77, 128.42, 127.94, 124.77, 117.45, 102.71, 71.16,
42.53.
3-(4-Methoxyphenyl)-2-(methylsulfonyl)-7-(benzyl-
oxy)-4H-1-benzopyran-4-one (1d). Compound 1d was
synthesized from 2-(methylthio)-3-phenyl-7-(benzyloxy)-
4H-1-benzopyran-4-one (3.24 g, 8.0 mmol) using Gen-
eral Method A, and 3.39 g (97%) of the title compound
was obtained as a white solid: mp 226 227 C; HRMS
calculated for C24H20NaO6S (M+Na)
+ 459.0878, found
459.0868. IR (KBr) 1648, 1624, 1609, 1578, 1569, 1510,
1439, 1332, 1292, 1248, 1162, 1138, 1101, 1030, 972, 840,
827, 774, 698, 613, 536, 525 cm 1; 1H NMR (250 MHz,
DMSO-d6) d 7.95 (d, J = 8.9 Hz, 1H), 7.33 7.49 (m,
6H), 7.17 7.21 (m, 3H), 6.94 (d, J = 8.7 Hz, 2H), 5.29
(s, 2H), 3.77 (s, 3H), 3.27 (s, 3H); 13C NMR
(62.9 MHz, DMSO-d6) d 176.57, 164.60, 160.32,
157.75, 157.32, 136.79, 132.83, 129.46, 129.10, 128.77,
127.95, 124.45, 121.67, 117.41, 117.38, 113.97, 101.67,
71.14, 55.96, 42.51.
General Method B for nucleophilic substitution
reactions of 2-(alkylsulfonyl)isoﬂavones (2a–d and 3a–d)
A solution of 7-alkoxy-3-aryl-2-(methylsulfonyl)-4H-1-
benzopyran-4-one (1.0 mmol) in DMF (1 mL) was
added to a stirred solution of a nucleophile (as a sodium
salt purchased or generated in situ by the treatment of
sodium hydride) in DMF (3 mL) at 0 C. After stirring
at 0 C for 0.5 h, most reactions were completed accord-
ing to TLC. The reaction mixture was allowed to warm
to room temperature over 1 h, then cooled to 0 C, and
quenched with saturated aqueous NH4Cl solution. After
the volatile solvents were removed in vacuo, the residual
solid was suspended in a mixture of water and EtOAc,
ultrasonicated for 5 min, and cooled to 0 C. Insoluble
solid was collected by ﬁltration and the ﬁlter cake was
washed with EtOAc/hexane mixture to give desire prod-
uct. The ﬁltrate was extracted with EtOAc twice
(2 · 10 mL), and the combined organic layer was
washed with brine, dried over MgSO4, ﬁltered, and con-
centrated under reduced pressure. The remnant was
puriﬁed by silica gel column chromatography (eluting
with MeOH/CHCl3) to collect additional product. The
combined solid was further puriﬁed by recrystallization.
2-(1H-Imidazol-1-yl)-7-methoxy-3-phenyl-4H-1-benzo-
pyran-4-one (2a). Compound 2a was synthesized from 7-
methoxy-2-(methylsulfonyl)-3-phenyl-4H-1-benzopyran-
4-one (0.330 g, 1.0 mmol) and sodium salt of imidazole
(0.180 g, 2.0 mmol, purchased) using General Method
B, and 0.231 g (73%) of the title compound was obtained
as a white solid (recrystallized from EtOAc): mp 217
219 C; HRMS calculated for C19H15N2O3 (M+H)+
319.1082, found 319.1060. IR (KBr) 1640, 1619, 1575,
1492, 1441, 1404, 1342, 1266, 1255, 1201, 1104, 1053,
1016, 953, 908, 834, 784, 754, 738, 703, 648 cm 1; 1H
NMR (400 MHz, DMSO-d6) d 7.98 (d, J = 8.9 Hz,
1H), 7.71 (s, 1H), 7.31 7.33 (m, 3H), 7.28 (d,
J = 2.4 Hz, 1H), 7.17 7.20 (m, 3H), 7.12 (dd, J = 8.9,
2.4 Hz, 1H), 6.93 (s, 1H), 3.89 (s, 3H); 13C NMR
(100 MHz, DMSO-d6) d 176.84, 165.15, 156.61, 151.04,
138.23, 131.39, 131.04, 129.92, 129.21, 129.00, 127.81,
120.31, 116.99, 166.20, 116.18, 101.65, 57.14. Elemental
analysis: Calcd for C19H14N2O3 (%): C, 71.69; H, 4.43;
N, 8.80. Found: C, 71.56; H, 4.49; N, 8.78.
2-(1H-Imidazol-1-yl)-7-methoxy-3-(4-methoxyphen-
yl)-4H-1-benzopyran-4-one (2b). Compound 2b was syn-
thesized from 7-methoxy-3-(4-methoxyphenyl)-2-(meth-
ylsulfonyl)-4H-1-benzopyran-4-one (0.36 g, 1.0 mmol)
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and sodium salt of imidazole (0.180 g, 2.0 mmol, pur-
chased) using General Method B, and 0.324 g (93%) of
the title compound was obtained as a white solid (recrys-
tallized from EtOH): mp 232 233 C; HRMS calculated
for C20H16N2NaO4 (M+Na)
+ 371.1008, found 371.1015.
IR (KBr) 1639, 1611, 1578, 1515, 1441, 1405, 1342,
1291, 1253, 1201, 1174, 1054, 1024, 831, 816,
747 cm 1; 1H NMR (400 MHz, CDCl3) d 8.15 (d,
J = 8.9 Hz, 1H), 7.62 (s, 1H), 7.12 (d, J = 8.7 Hz,
2H), 7.00 7.03 (m, 2H), 6.96 (s, 1H), 6.89 6.91 (m,
3H), 3.92 (s, 3H), 3.80 (s, 3H); 13C NMR (100 MHz,
CDCl3) d 177.20, 164.98, 160.18, 156.18, 150.21,
137.22, 131.71, 130.38, 128.41, 122.28, 118.77, 117.12,
115.46, 115.01, 114.43, 100.46, 56.41, 55.67. Elemental
analysis: Calcd for C20H16N2O4 (%): C, 68.96; H, 4.63;
N, 8.04. Found: C, 68.73; H, 4.72; N, 7.94.
2-(1H-Imidazol-1-yl)-3-phenyl-7-(benzyloxy)-4H-
1-benzopyran-4-one (2c). Compound 2c was synthesized
from 2-(methylsulfonyl)-3-phenyl-7-(benzyloxy)-4H-1-
benzopyran-4-one (0.41 g, 1.0 mmol) and sodium salt
of imidazole (0.180 g, 2.0 mmol, purchased) using Gen-
eral Method B, and 0.323 g (82%) of the title compound
was obtained as a white solid (recrystallized from
EtOAc): mp 152 153 C; HRMS calculated for
C25H19N2O3 (M+H)
+ 395.1395, found 395.1396. IR
(KBr) 1633, 1610, 1572, 1494, 1441, 1402, 1389, 1336,
1251, 1193, 1150, 1103, 1094, 1051, 1017, 991, 908,
839, 790, 740, 699 cm 1; 1H NMR (400 MHz, CDCl3)
d 8.17 (d, J = 8.9 Hz, 1H), 7.58 (s, 1H), 7.35 7.45 (m,
8H), 7.19 7.21 (m, 2H), 7.10 (dd, J = 8.9, 2.3 Hz, 1H),
6.99 (s, 1H), 6.97 (d, J = 2.3 Hz, 1H), 6.92 (s, 1H),
5.19 (s, 2H); 13C NMR (100 MHz, CDCl3) d 176.90,
164.06, 156.12, 150.35, 137.19, 135.85, 130.53, 130.41,
129.47, 129.26, 129.13, 128.96, 128.49, 127.91, 118.77,
117.32, 116.08, 114.82, 101.58, 71.14. Elemental analy-
sis: Calcd for C25H18N2O3 (%): C, 76.13; H, 4.60; N,
7.10. Found: C, 76.24; H, 4.71; N, 7.10.
2-(1H-Imidazol-1-yl)-3-(4-methoxyphenyl)-7-(benz-
yloxy)-4H-1-benzopyran-4-one (2d). Compound 2d was
synthesized from 3-(4-methoxyphenyl)-2-(methylsulfo-
nyl)-7-(benzyloxy)-4H-1-benzopyran-4-one (0.71 g,
1.63 mmol) and sodium salt of imidazole (0.30 g,
3.25 mmol, purchased) using General Method B, and
0.604 g (87%) of the title compound was obtained as a
white solid (recrystallized from EtOAc): mp 160
161 C; HRMS calculated for C26H21N2O4 (M+H)+
425.1501, found 425.1511. IR (KBr) 1637, 1613, 1577,
1512, 1439, 1403, 1339, 1293, 1245, 1194, 1175, 1098,
1055, 1018, 908, 823, 748, 700, 654 cm 1; 1H NMR
(400 MHz, CDCl3) d 8.16 (d, J = 8.9 Hz, 1H), 7.61 (s,
1H), 7.36 7.45 (m, 5H), 7.12 (d, J = 8.7 Hz, 2H), 7.09
(dd, J = 8.9, 2.3 Hz, 1H), 7.00 (s, 1H), 6.96 (d,
J = 2.3 Hz, 1H), 6.95 (s, 1H), 6.90 (d, J = 8.7 Hz, 2H),
5.18 (s, 2H), 3.80 (s, 3H); 13C NMR (100 MHz, CDCl3)
d 177.17, 163.99, 160.19, 156.09, 150.23, 137.22, 135.87,
131.70, 130.38, 129.25, 128.94, 128.49, 127.90, 122.25,
118.77, 117.31, 116.01, 115.02, 114.47, 101.54, 71.12,
55.67. Elemental analysis: Calcd for C26H20N2O4 (%):
C, 73.57; H, 4.75; N, 6.60. Found: C, 73.54; H, 4.82;
N, 6.55.
7-Methoxy-3-phenyl-2-(1H-1,2,4-triazol-1-yl)-4H-
1-benzopyran-4-one (3a). Compound 3a was synthesized
from 7-methoxy-2-(methylsulfonyl)-3-phenyl-4H-1-benzo-
pyran-4-one (0.165 g, 0.5 mmol) and sodium salt of
1,2,4-triazole (0.091 g, 1.0 mmol, purchased) using Gen-
eral Method B, and 0.144 g (90%) of the title compound
was obtained as a white solid (recrystallized from
EtOAc): mp 188.5 189.5 C; HRMS calculated for
C18H13N3NaO3 (M+Na)
+ 342.0855, found 342.0843.
IR (KBr) 1643, 1619, 1575, 1502, 1429, 1337, 1262,
1217, 1203, 1124, 1104, 1060, 993, 920, 837, 831, 785,
755, 705, 662 cm 1; 1H NMR (400 MHz, DMSO-d6) d
8.63 (s, 1H), 8.21 (s, 1H), 8.01 (d, J = 8.9 Hz, 1H),
7.28 7.29 (m, 4H), 7.11 7.16 (m, 3H), 3.89 (s, 3H); 13C
NMR (100 MHz, DMSO-d6) d 176.56, 165.48, 156.70,
153.62, 150.08, 147.29, 130.79, 130.67, 129.01, 128.92,
127.98, 119.39, 117.14, 116.57, 101.69, 57.25. Elemental
analysis: Calcd for C18H13N3O3 (%): C, 67.71; H, 4.10;
N, 13.16. Found: C, 67.60; H, 4.14; N, 13.06.
2-(1H-Imidazolyl-2-thio)-7-methoxy-3-phenyl-4H-
1-benzopyran-4-one (3b). Compound 3b was synthesized
from 7-methoxy-2-(methylsulfonyl)-3-phenyl-4H-1-benzo-
pyran-4-one (0.165 g, 0.5 mmol), 2-mercaptoimidazole
(0.153 g, 1.5 mmol), and sodium hydride (0.036 g,
1.5 mmol) using General Method B, and 0.156 g (89%)
of the title compound was obtained as a white solid
(recrystallized from EtOH): mp 248 250 C (decom-
posed); HRMS calculated for C19H14N2NaO3S
(M+Na)+ 373.0623, found 373.0640. IR (KBr) 3434,
1622, 1589, 1537, 1437, 1376, 1349, 1331, 1260, 1205,
1104, 1028, 939, 831, 784, 760, 711 cm 1; 1H NMR
(400 MHz, DMSO-d6) d 12.95 (br s, 1H), 7.91 (d,
J = 8.9 Hz, 1H), 7.38 7.47 (m, 4H), 7.33 7.35 (m, 2H),
7.11 (s, 1H), 7.04 (dd, J = 8.9, 2.3 Hz, 1H), 6.55 (d,
J = 2.3 Hz, 1H), 3.81 (s, 3H); 13C NMR (100 MHz,
DMSO-d6) d 173.85, 164.59, 160.91, 158.42, 132.57,
131.69, 131.48, 130.14, 129.27, 129.19, 127.97, 123.41,
122.38, 117.12, 115.75, 100.79, 56.99. Elemental analy-
sis: Calcd for C19H14N2O3S (%): C, 71.69; H, 4.43; N,
8.80. Found: C, 71.56; H, 4.49; N, 8.78.
7-Methoxy-2-(1-methyl-1H-imidazolyl-2-thio)-3-phen-
yl-4H-1-benzopyran-4-one (3c). Compound 3c was syn-
thesized from 7-methoxy-2-(methylsulfonyl)-3-phenyl-
4H-1-benzopyran-4-one (0.165 g, 0.5 mmol), 2-mer-
capto-1-methylimidazole (0.171 g, 1.5 mmol), and so-
dium hydride (0.036 g, 1.5 mmol) using General
Method B, and 0.175 g (96%) of the title compound
was obtained as a white solid (recrystallized from
EtOAc): 172 173 C; HRMS calculated for
C20H17N2O3S (M+H)
+ 365.0960, found 365.0955. IR
(KBr) 1640, 1618, 1590, 1499, 1437, 1368, 1344, 1253,
1198, 1099, 1016, 939, 783, 756, 698 cm 1; 1H NMR
(400 MHz, DMSO-d6) d 7.90 (d, J = 9.0 Hz, 1H), 7.51
(d, J = 1.0 Hz, 1H), 7.40 7.48 (m, 3H), 7.34 7.36 (m,
2H), 7.11 (d, J = 1.2 Hz, 1H), 7.03 (dd, J = 9.0, 2.3 Hz,
1H), 6.57 (d, J = 2.3 Hz, 1H), 3.82 (s, 3H), 3.68 (s,
3H); 13C NMR (100 MHz, DMSO-d6) d 173.88,
164.60, 160.85, 158.42, 132.59, 131.89, 131.46, 131.06,
129.30, 129.22, 127.98, 126.94, 123.53, 117.15, 115.70,
100.96, 57.02, 34.68. Elemental analysis: Calcd for
4068
C20H16N2O3S (%): C, 65.92; H, 4.43; N, 7.69. Found: C,
65.68; H, 4.46; N, 7.62.
7-Methoxy-3-phenyl-2-(1H-1,2,4-triazolyl-3-thio)-
4H-1-benzopyran-4-one (3d). Compound 3d was synthe-
sized from 7-methoxy-2-(methylsulfonyl)-3-phenyl-4H-
1-benzopyran-4-one (0.165 g, 0.5 mmol), 1H-1,2,4-tri-
azole-3-thiol (0.152 g, 1.5 mmol), and sodium hydride
(0.036 g, 1.5 mmol) using General Method B, and
0.075 g (43%) of the title compound was obtained as a
pale yellow solid (recrystallized from EtOH): mp 246
247 C; HRMS calculated for C18H13N3NaO3S
(M+Na)+ 374.0575, found 374.0586. IR (KBr) 1612,
1582, 1502, 1440, 1379, 1349, 1262, 1201, 1185, 1104,
1014, 969, 939, 830, 783, 758, 700 cm 1; 1H NMR
(400 MHz, DMSO-d6) d 8.69 (s, 1H), 7.91 (d,
J = 8.9 Hz, 1H), 7.36 7.45 (m, 3H), 7.32 7.34 (m, 2H),
7.04 (dd, J = 8.9, 2.3 Hz, 1H), 6.73 (d, J = 2.3 Hz, 1H),
3.81 (s, 3H); 13C NMR (100 MHz, DMSO-d6) d 174.51,
164.83, 159.47, 158.67, 146.80, 132.74, 131.27, 129.33,
129.17, 127.96, 126.01, 117.02, 116.01, 100.81, 56.99. Ele-
mental analysis: Calcd for C18H13N3O3S (%): C, 61.53;
H, 3.73; N, 11.96. Found: C, 61.27; H, 3.76; N, 11.86.
Enzymology
Preparation of human placental microsomes. Hu-
man term placentas were processed immediately after
delivery from The Ohio State University Hospitals at
4 C. The placenta was washed with normal saline and
connective and vascular tissue was removed. Micro-
somes were prepared from the remaining tissue using
the method described by Kellis and Vickery.20 Micro-
somal suspensions were stored at 80 C until required.
Inhibition study. Inhibition of human placental
aromatase was determined by monitoring the amount
of 3H2O released as the enzyme converts [1b-
3H]and-
rost-4-ene-3,17-dione to estrone. Ten inhibitor concen-
trations ranging from 100 nM to 50 lM were
evaluated. Aromatase activity assays were carried in
0.1 M potassium phosphate buﬀer (pH 7.0) with 5%
propylene glycol. All samples contained a NADPH
regenerating system consisting of 2.85 mM glucose-6-
phosphate, 1.8 mM NADP+ and 1.5 units of glucose-
6-phosphate dehydrogenase (Sigma, St. Louis, MO).
Samples contained 100 nM androst-4-ene-3,17-dione
(400,000 450,000 dpm). Reactions were initiated with
the addition of 50 lg microsomal protein. The total
incubation volume was 2.0 mL. Incubations were al-
lowed to proceed for 15 min in a shaking water bath
at 37 C. Reactions were quenched by the addition of
2.0 mL of chloroform. Samples were then vortexed
and centrifuged for 5 min and the aqueous layer was re-
moved. The aqueous layer was subsequently extracted
twice in the same manner with 2.0 mL chloroform. A
0.5 mL aliquot of the ﬁnal aqueous layer was combined
with 5 mL 3a70B scintillation cocktail (Research Prod-
ucts International Corp., Mt. Prospect, IL) and the
amount of radioactivity determined. Each sample was
run in triplicate and background values were determined
with microsomal protein inactivated by boiling. Samples
containing 50 lM (±) aminoglutethimide (Sigma, St.
Louis, MO) were used a positive control. IC50 dose re-
sponse data were analyzed with the Graphpad Prism
(Version 3.0) program.
Kinetic study. Enzyme kinetic studies of com-
pounds 2a d were conducted to investigate the nature
of aromatase inhibition. Michaelis-Menten enzyme
kinetic parameters were determined by varying the con-
centration of androst-4-ene-3,17-dione from 50 to
500 nM in the presence of a ﬁxed concentrations of 0,
100, 500, 2000 nM (2a,c) and 0, 2000, 5000, 10,000 nM
(2b,d). Assay conditions were the same as those de-
scribed in the IC50 studies except reactions were initiated
by the addition of 15 lg microsomal protein. Analysis of
the enzyme kinetic data was performed with the
weighted linear regression analysis previously described
by Cleland.21
Determination of P450 diﬀerence spectra. Immuno-
aﬃnity-puriﬁed human placental cytochrome P450 aro-
matase (Hauptman-Woodward Medical Research
Institute, Buﬀalo, NY) was diluted to 7.0 lg/mL with
0.1 M Tris Buﬀer (pH 7.4) in a 50 lL quartz UV cell,
and the absorbance was scanned from 350 to 500 nm.
0.1 M Tris Buﬀer (pH 7.4) was used as a reference. Com-
pounds 2a and 3a were introduced into the sample cell in
1 lL of ethanol for a ﬁnal concentration of 50 lM, and
the spectrum was rescanned at the aforementioned
wavelength range. Multiple scans were taken to ensure
spectrum stability for aromatase and aromatase/inhibi-
tor mixtures. Absorbance values of aromatase were sub-
tracted from the aromatase/inhibitor values to generate
the diﬀerence spectrum.
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